The transport of L‐6‐fluorodopa and its metabolites from blood to cerebrospinal fluid and brain

The transport of L‐6‐fluorodopa and its major metabolites from the blood to the brain, cerebrospinal fluid (CSF), and muscle was studied in carbidopa‐pretreated cynomolgus monkeys. A bolus intravenous injection of ¹⁸F‐L‐6‐fluorodopa was followed by serial positron emission tomography scans and sampling of cisternal CSF and arterial blood. The relative concentrations of L‐6‐fluorodopa and its metabolites were determined in blood plasma and CSF by highperformance liquid chromatography. Raising the blood concentration of phenylanine by intraperitoneal injection markedly reduced the accumulation of tracer in the brain. This indicates that L‐6‐fluorodopa and 3‐O‐methylfluorodopa, like native L‐dopa and its O‐methylated derivative, are transported at the brain capillary by the large neutral amino acid carrier‐mediated system, which is subject to saturation and competition by other large neutral amino acids (such as phenylalanine) at physiological plasma concentrations. In contrast, administration of phenylalanine had no effect on the accumulation of tracer either in muscle, or as L‐6‐fluorodopa and 3‐O‐methylfluorodopa, in CSF. This suggests that the transport of L‐dopa and its derivatives at the blood‐CSF barrier differs from the transport at the blood‐brain barrier and also that measurement of CSF L‐dopa is not a good index of the transport and pharmacokinetics of L‐dopa in the brain. However, the effect of phenylalanine administration in reducing the concentration of fluorohomovanillic acid in the CSF suggests that the concentration of homovanillic acid in the CSF is an accurate reflection of dopamine turnover in the brain.